ɪt wʌz ɐpɹˈuːvd baɪ ðɪ ˌɛfdˌiːˈeɪ ɪn mˈɑːɹtʃ nˈaɪntiːnhˈʌndɹɪd nˈaɪnti wˈʌn ˌʌndɚ ðə tɹˈeɪd nˈeɪm lˈuːkaɪn fɔːɹ ɐksˌɛlɚɹˈeɪʃən ʌv wˈaɪt blˈʌd sˈɛl ɹᵻkˈʌvɚɹi fˈɑːloʊɪŋ ˌɔːɾoʊlˈɑːɡəs bˈoʊn mˈæɹoʊ tɹænsplɐntˈeɪʃən ɪn pˈeɪʃənts wɪð nˈɑːnhˈɑːdʒkɪnz lɪmfˈoʊmə, ɐkjˈuːt lˌɪmfəsˈɪɾɪk luːkˈiːmiə, ɔːɹ hˈɑːdʒkɪnz dɪzˈiːz.
It was approved by the FDA in March 1991 under the trade name Leukine for acceleration of white blood cell recovery following autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease.